• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.82% Nasdaq Up0.70%

    More On BNO.AX



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Bionomics Ltd. (BNO.AX)

    0.29 0.00(0.00%) 7:59PM EDT
    ProfileGet Profile for:
    Bionomics Ltd.
    31 Dalgleish Street
    Thebarton, SA 5031
    Australia - Map
    Phone: 61 8 8354 6100
    Fax: 61 8 8354 6199
    Website: http://www.bionomics.com.au

    Index Membership:N/A
    Full Time Employees:N/A

    Business Summary 

    Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company’s product pipeline includes BNC210, a novel and proprietary negative allosteric modulator, which is in Phase II clinical trials and Phase I multiple ascending dose trials for the treatment of generalized anxiety disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in alzheimers's disease; BNC101, a monoclonal antibody, which has completed preclinical studies that targets cancer stem cells; and BNC105, a novel compound to disrupt the blood vessels that nourish tumors in cancer treatment. It also offers contract research services. The company has collaboration agreement with Merck & Co. to develop compounds targeting cognitive impairment in conditions, such as ADHD, alzheimer’s disease, parkinson’s disease, and schizophrenia. The company has a strategic collaboration with Merck & Co. Inc. for the discovery and development of drug candidates for the treatment of chronic and neuropathic pain. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Bionomics Ltd.

    Key Executives 
    Dr. Deborah Rathjen B.Sc. (Hons.), Ph.D., M.A.I.C.D., FTSE, 58
    Chief Exec. Officer, Managing Director and Exec. Director
    Ms. Melanie Young BCom, ACA, 46
    Chief Financial Officer
    Dr. Jens D. Mikkelsen M.D., Ph.D.,
    Chief Scientific Officer
    Mr. Jack Moschakis BEc, DipLaw(BAB), GDipBA, FCIS,
    Legal Counsel and Company Sec.
    Mr. Anthony Colasin MBA,
    Chief Bus. Officer
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in AUD.